Aaron Seth Kesselheim
Aaron Seth Kesselheim, MD, JD, MPH
Professor of Medicine

Aaron S. Kesselheim MD JD MPH is a Professor of Medicine at Harvard Medical School and a faculty member in the Division of Pharmacoepidemiology and Pharmacoeconomics in the Department of Medicine at Brigham and Women’s Hospital. Within the Division, Aaron created and leads the Program On Regulation, Therapeutics, And Law (PORTAL, www.PORTALresearch.org), an interdisciplinary research core focusing on intersections among prescription drugs and medical devices, patient health outcomes, and regulatory practices and the law. PORTAL is now among the largest, independent academic centers focusing on these issues in the country (Twitter: @PORTAL_research, @akesselheim). Dr. Kesselheim received his medical and legal training at the University of Pennsylvania and his M.P.H. at the Harvard School of Public Health. Author of over 450 publications in the peer-reviewed medical and health policy literatures, Aaron has testified before Congress on pharmaceutical policy, medical device regulation, generic drugs, and modernizing clinical trials, is a member of the FDA Peripheral and Central Nervous System Advisory Committee, and served on a National Academies of Science, Engineering and Medicine consensus committees on addressing the opioid epidemic and bioidentical hormone replacement. At the HMS Center for Bioethics, he co-teaches a course on health policy, law, and bioethics and organizes the monthly policy and ethics consortium.

Publications View
Fool Me Twice? The Reemergence of Rofecoxib and the Orphan Drug Act.
Authors: Authors: Lee TT, Solomon DH, Kesselheim AS.
Ann Intern Med
View full abstract on Pubmed
Variation in Prescription Drug Prices by Retail Pharmacy Type: A National Cross-sectional Study.
Authors: Authors: Luo J, Kulldorff M, Sarpatwari A, Pawar A, Kesselheim AS.
Ann Intern Med
View full abstract on Pubmed
Changes in Price for Generic Drugs in the USA, 2008-2016.
Authors: Authors: Dave CV, Brill G, Kesselheim AS.
J Gen Intern Med
View full abstract on Pubmed
Patients' Knowledge of Key Messaging in Drug Safety Communications for Zolpidem and Eszopiclone: A National Survey.
Authors: Authors: Kesselheim AS, Sinha MS, Rausch P, Lu Z, Tessema FA, Lappin BM, Zhou EH, Dal Pan GJ, Zwanziger L, Ramanadham A, Loughlin A, Enger C, Avorn J, Campbell EG.
J Law Med Ethics
View full abstract on Pubmed
Challenges and Opportunities for Biomarker Validation.
Authors: Authors: Hey SP, D'Andrea E, Jung EH, Tessema F, Luo J, Gyawali B, Kesselheim AS.
J Law Med Ethics
View full abstract on Pubmed
Potential Medicare Savings From Generic Substitution and Therapeutic Interchange of ACE Inhibitors and Angiotensin-II-Receptor Blockers.
Authors: Authors: Growdon ME, Sacks CA, Kesselheim AS, Avorn J.
JAMA Intern Med
View full abstract on Pubmed
Assessing the Justification, Funding, Success, and Survival Outcomes of Randomized Noninferiority Trials of Cancer Drugs: A Systematic Review and Pooled Analysis.
Authors: Authors: Gyawali B, Tessema FA, Jung EH, Kesselheim AS.
JAMA Netw Open
View full abstract on Pubmed
Spending on World Health Organization essential medicines in Medicare Part D, 2011-15: retrospective cost analysis.
Authors: Authors: Li DG, Najafzadeh M, Kesselheim AS, Mostaghimi A.
BMJ
View full abstract on Pubmed
Impact of State Laws Restricting Opioid Duration on Characteristics of New Opioid Prescriptions.
Authors: Authors: Dave CV, Patorno E, Franklin JM, Huybrechts K, Sarpatwari A, Kesselheim AS, Bateman BT.
J Gen Intern Med
View full abstract on Pubmed
Multimodal Analysis of FDA Drug Safety Communications: Lessons from Zolpidem.
Authors: Authors: Kesselheim AS, Sinha MS, Campbell EG, Schneeweiss S, Rausch P, Lappin BM, Zhou EH, Avorn J, Dal Pan GJ.
Drug Saf
View full abstract on Pubmed

Address: 
Brigham and Women's Hospital
Boston, MA 02120